Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20211206053288N1
IRCT20211206053288N1
Not yet recruiting
Phase 3

Evaluation the effects of atomoxetine on the improvement of cognitive impairment in Behcet’s disease patients

Tehran University of Medical Sciences0 sites40 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
40
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Individuals diagnosed with Behcet's disease according to ICBD (International Criteria for Behcet's Disease) criteria
  • •Presence of cognitive impairment detected by following tests: Forward digit span, Backward digit span, Trail making A, Trail making B, Verbal fluency

Exclusion Criteria

  • •History of cognitive impairment before affected by Behcet's disease
  • •Substance use
  • •History of adverse reactions to Atomoxetine

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophrenia
IRCT20101130005280N31Mashhad University of Medical Sciences42
Active, not recruiting
Phase 1
Evaluation of the effect of Atomoxetine on impulsive state of High impulsive Tourette’s patients.
EUCTR2019-004455-36-FRCHU DE POITIERS45
Completed
Phase 3
Study of therapeutic effects of Atomoxtein in reducing the symptoms of patients with recurrent vasovagal syncope
IRCT20180125038507N1Tehran University of Medical Sciences50
Recruiting
Phase 2
Effectiveness of Atomoxetine treatment for methamphetamine use disorderOther stimulants dependence syndrome.Dependence syndrome: A cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and that typically include a strong desire to take the drug, difficulties in controlling its use, persisting in its use despiteF15.24
IRCT2017070234844N1Tehran University of Medical Sciences (TUMS), Vice-chancellor for Research90
Active, not recruiting
Not Applicable
Effect of Atomoxetine and a standardized behavior therapy on attention deficits in adult ADHD - Atomoxetine and adult ADHDAdult Attention Deficit Hyperactivity DisorderMedDRA version: 8.1Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorder
EUCTR2006-004073-10-DEniversity of Giessen